Company Profiles

driven by the PitchBook Platform

Lux Biosciences

Description

Developer of medications and drugs designed to treat ophthalmic diseases. The company's medications and drugs include LX201, silicone matrix ocular implant and Luveniq, an oral form of drug inhibitor voclosporin, enabling healthcare professionals to treat serious ophthalmic diseases.

2006

Founded

OOB

Status

11-50

Employees

Out of Business

Latest Deal Type

$152M

Total Amount Raised

7

Investors

Description

Developer of medications and drugs designed to treat ophthalmic diseases. The company's medications and drugs include LX201, silicone matrix ocular implant and Luveniq, an oral form of drug inhibitor voclosporin, enabling healthcare professionals to treat serious ophthalmic diseases.

Website:

www.luxbio.com

Ownership Status

Out of Business

Financing Status

Formerly VC-Backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery

Primary Office

Harborside Financial Center Plaza 10 14th Floor Jersey City, NJ 07302United States +1 (201) 946-0551
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Lux Biosciences's full profile, request a free trial.

    Lux Biosciences Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Lux Biosciences Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    Lux Biosciences Investors (7)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Hatteras Venture PartnersVenture CapitalMinority000 0000000 0000
    HBM Healthcare InvestmentsVenture CapitalMinority000 0000000 0000
    HBM PartnersInvestment BankMinority000 0000000 0000
    International Biotechnology TrustOtherMinority000 0000000 0000
    NovoCorporate Venture CapitalMinority000 0000000 0000
    Hatteras Venture Partners Venture Capital
    HBM Healthcare Investments Venture Capital
    HBM Partners Investment Bank
    International Biotechnology Trust Other
    Novo Corporate Venture Capital

    Lux Biosciences Executive Team (2)

    NameTitleBoard
    Seat
    Contact
    Info
    Dean MitchellPresident, Chief Executive Officer and Board Member
    Eddy Anglade MDCo-Founder & Chief Medical Officer
    Dean Mitchell President, Chief Executive Officer and Board Member
    Eddy Anglade MD Co-Founder & Chief Medical Officer

    Lux Biosciences Board Members (4)

    NameRepresentingRoleSinceContact
    Info
    Axel BolteLux BiosciencesBoard Member000 0000
    David Schnell MDProspect Venture PartnersCo-Founder, Partner & Managing Director000 0000
    Paul ChaneyLux BiosciencesBoard Member000 0000
    Thomas DyrbergLux BiosciencesBoard Member000 0000
    Axel Bolte Board Member Lux Biosciences
    David Schnell MD Co-Founder, Partner & Managing Director Prospect Venture Partners
    Paul Chaney Board Member Lux Biosciences
    Thomas Dyrberg Board Member Lux Biosciences
    Request full access to PitchBook